BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

Engineered ADAM17 cleavage site in CARs tunes receptor shedding to to control CAR T signaling and exhaustion

BC Staff
June 3, 2026 12:30 AM UTC

BCIQ Company Profiles

Stanford University

BCIQ Target Profiles

ADAM metallopeptidase domain 17 (ADAM17)

L selectin (CD62L) (SELL)

BCIQ Company Profiles

Stanford University

BCIQ Target Profiles

ADAM metallopeptidase domain 17 (ADAM17)

L selectin (CD62L) (SELL)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2026 BioCentury Inc. All Rights Reserved.
Copyright © 2026 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS